Alpine Immune Sciences, Inc. - Common Stock (NQ:ALPN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alpine Immune Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 25, 2024

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.

Via Benzinga

Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday ↗

January 25, 2024

U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings.

Via Benzinga

Topics Stocks

Beyond The Numbers: 7 Analysts Discuss Alpine Immune Sciences Stock ↗

December 22, 2023

Via Benzinga

The Latest Analyst Ratings for Alpine Immune Sciences ↗

November 15, 2023

Via Benzinga

Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 22, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie

December 21, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 18, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

What 8 Analyst Ratings Have To Say About Alpine Immune Sciences ↗

October 18, 2023

Via Benzinga

Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference

November 20, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

November 15, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

November 14, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

November 13, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 07, 2023

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.

Via Benzinga

Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 07, 2023

U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Alpine Immune Sciences Announces Pricing of $150 Million Public Offering

November 06, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Announces Proposed Public Offering

November 06, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

November 03, 2023

The Benzinga Stock Whisper Index uses proprietary data to look at stocks with increased interest from investors.

Via Benzinga

Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting

November 03, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Apple, Coinbase Global, Fortinet And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

November 03, 2023

U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

November 02, 2023

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 02, 2023

Via Benzinga

Why Is Alpine Immune Sciences Stock Trading Higher Today? ↗

November 02, 2023

Alpine Immune Sciences Inc (NASDAQ: ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology

Via Benzinga

Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday ↗

November 02, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

November 02, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

October 30, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023 ↗

October 18, 2023

Via Benzinga

Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023

October 13, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

IgAN Treatment Market Worth Over $6B By 2032: Analyst Bearish On Povetacicept's Promising Role ↗

October 05, 2023

RBC Capital Markets initiated coverage on Alpine Immune Sciences Inc (NASDAQ: ALPN), noting that the autoimmune disease market (over $165 billion) is meaningful for the company's lead candidate -...

Via Benzinga

Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)

October 04, 2023

From Alpine Immune Sciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023 ↗

October 05, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.